Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1141958

	registered interest
	date	24/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Pertuzumab
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what advice they provide to clinicians for the use of Pertuzumab rather than Herceptin for the treatment of HER2+ breast cancer.
	tabling member printed	Lord Willis of Knaresborough
	uin	HL17502
	answer	answer is ministerial correction date of answer 25/07/2019 answer text <p>The National Institute for Health and Care Excellence (NICE) is the independent body responsible for making recommendations for the National Health Service on whether drugs and other treatments represent a clinically and cost effective use of NHS resources.</p><p>NICE has recommended the following drugs for the treatment of HER2-positive breast cancer: trastuzumab emtansine (Kadcyla) for treating HER2-positive advanced breast cancer after trastuzumab (Herceptin) and a taxane; pertuzumab (Perjeta) with trastuzumab (Herceptin) and docetaxel for treating HER2-positive breast cancer; pertuzumab (Perjeta) for the neoadjuvant treatment of HER2-positive breast cancer; and pertuzumab (Perjeta) for adjuvant treatment of HER2-positive early stage breast cancer.</p><p>NHS commissioners are legally required to fund drugs recommended in NICE technology appraisal guidance. It is for clinicians to decide on the most appropriate treatment for an individual patient based on their clinical judgement and in discussion with the patient.</p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL17501 question first answered 25/07/2019 16:45:03 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	4151 label Biography information for Lord Willis of Knaresborough

1141957

	registered interest
	date	24/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Breast Cancer: Drugs
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what are the drugs approved by NICE to treat HER2+ breast cancer; and what assessment they have made of the efficacy of such drugs.
	tabling member printed	Lord Willis of Knaresborough
	uin	HL17501
	answer	answer is ministerial correction date of answer 25/07/2019 answer text <p>The National Institute for Health and Care Excellence (NICE) is the independent body responsible for making recommendations for the National Health Service on whether drugs and other treatments represent a clinically and cost effective use of NHS resources.</p><p>NICE has recommended the following drugs for the treatment of HER2-positive breast cancer: trastuzumab emtansine (Kadcyla) for treating HER2-positive advanced breast cancer after trastuzumab (Herceptin) and a taxane; pertuzumab (Perjeta) with trastuzumab (Herceptin) and docetaxel for treating HER2-positive breast cancer; pertuzumab (Perjeta) for the neoadjuvant treatment of HER2-positive breast cancer; and pertuzumab (Perjeta) for adjuvant treatment of HER2-positive early stage breast cancer.</p><p>NHS commissioners are legally required to fund drugs recommended in NICE technology appraisal guidance. It is for clinicians to decide on the most appropriate treatment for an individual patient based on their clinical judgement and in discussion with the patient.</p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL17502 question first answered 25/07/2019 16:45:03 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	4151 label Biography information for Lord Willis of Knaresborough

1141959

	registered interest
	date	24/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Breast Cancer: Clinical Trials
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government which clinical trials are currently recruiting patients with HER2+ breast cancer.
	tabling member printed	Lord Willis of Knaresborough
	uin	HL17503
	answer	answer is ministerial correction date of answer 07/08/2019 answer text <p>The Department’s National Institute for Health Research (NIHR) is currently recruiting to 15 clinical trials for people with HER2+ breast cancer via its Clinical Research Network. The majority of these are commercially funded. To date, a total of 7,986 participants have been recruited to these 15 trials.</p><p>Of the 15 clinical trials, 12 are commercially sensitive, with appropriate cost recovery from the companies. The data for these commercial trials has been provided from the relevant companies as ‘commercial in confidence’ hence we are unable to provide details about these trials such as their titles.</p><p>However, the three clinical trials which are not commercially sensitive are:</p><p>- Cancer Research UK; NIHR Evaluation, Trials and Studies Co-ordinating Centre (NETSCC). Title: The UK plasma based Molecular profiling of Advanced breast cancer to inform Therapeutic Choices (plasmaMATCH);</p><p>- Cancer Research UK. Title: Response to Optimal Selection of neo-adjuvant Chemotherapy in Operable breast cancer; and</p><p>- Medical Research Council. Title: A mechanistic non-invasive imaging study of HER2 expression in breast cancer using [18F]GE-226 positron emission tomography.</p> answering member printed Baroness Blackwood of North Oxford question first answered 07/08/2019 11:43:14 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	4151 label Biography information for Lord Willis of Knaresborough